Source: Multiple Myeloma News — ScienceDaily
Researchers have found a new type of therapy to be effective for patients with a particular type of bone marrow cancer that is resistant to several standard therapies.
Read More
Recent Content
- Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN
- Identification of KDM4C as a gene conferring drug resistance in multiple myeloma
- Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL)
- Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy
- TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors
- FDA panel backs residual disease as ‘reasonable surrogate’ endpoint in myeloma trials
- In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
- Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
- Simulation of cancer progression in bone by a virtual thermal flux with a case study on lumbar vertebrae with multiple myeloma
- Sahin I, Kawano Y, Sklavenitis-Pistofidis R, et al. Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Adv. 2019;3(7):995-1002